SHANGHAI, April 15,
2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY)
("The9"), an established Internet company, today announced that its
investee WM Therapeutics Co., Ltd. (未名脑脑) ("WM Therapeutics")
has achieved revolutionary breakthroughs in the proprietarily
developed research and development of antidepressant drug precision
treatment. WM Therapeutics' GenAI multi-dimensional omics drug
clinical research technology has made significant progress in new
clinical trial, bringing new hope to depression patients.
WM Therapeutics, a world-leading precision brain disease medical
company based on GenAI and multi-dimensional omics biomarker
technology, today announced its latest clinical trial results. This
breakthrough research has made significant progress in depression
drug research using multi-dimensional and multi-omics AI digital
biomarkers. In a recently completed clinical trial, the platform
successfully identified effective subtype in drug treatment of
depression with a p-value of 0.004, which is significant in
statistics. This indicated a profound understanding of depression
patients and an innovation in future treatment options.
Over the past decade, there has been little progress in drug
development for depression, leaving tens of thousands of patients
suffering from this disease. WM Therapeutics' new technology not
only indicated the birth of a new generation of precision
antidepressant treatments, but also marked a major improvement over
current treatments.
"This achievement not only demonstrates the capabilities of our
powerful GenAI platform, but also brings new hope to patients with
depression around the world. We are committed to extend the
boundaries of science and technology to help patients suffering
from the disease with scientific innovation," said Ms. Yan Gao, Founder and CEO of WM Therapeutics.
Currently, the number of patients with depression worldwide is
estimated to be approximately 3.8% of the population. This means
approximately 280 million people worldwide are affected by
depression. 5% of adults have depression problem. With the
announcement of this result, WM Therapeutics hopes to accelerate
the commercialization process of its antidepressant drug precision
treatment and provide more effective treatment options for the
global market.
Safe Harbor Statement
This current report contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar statements. Such
statements are based upon management's current expectations and
current market and operating conditions and relate to events that
involve known or unknown risks, uncertainties and other factors,
all of which are difficult to predict and many of which are beyond
The9's control. The9 may also make written or oral forward-looking
statements in its periodic reports to the U.S. Securities and
Exchange Commission ("SEC"), in its annual report to shareholders,
in press releases and other written materials and in oral
statements made by its officers, directors or employees to third
parties. Statements that are not historical facts, including
statements about The9's beliefs and expectations, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties. A number of factors could cause
actual results to differ materially from those contained in any
forward-looking statement, including but not limited to the
following: The9's goal and strategies; The9's expansion plans;
The9's future business development, financial condition and results
of operations; The9's expectations regarding demand for, and market
acceptance of, its products and services; The9's expectations
regarding keeping and strengthening its relationships with business
partners it collaborates with; general economic and business
conditions; and assumptions underlying or related to any of the
foregoing. Further information regarding these and other risks is
included in The9's filings with the SEC. All information provided
in this announcement is as of the date hereof, and The9 does not
undertake any obligation to update any forward-looking statement,
except as required under applicable law.
About Therapeutics Co., Ltd. (未名脑脑)
WM Therapeutics is a world-leading GenAI precision treatment
company for brain diseases. It is developed based on AI
multidimensional omics data analysis technology, GenAI and digital
human technology, AI large language model driven drug discovery
technology and brain-computer interface original research
technology. The central nervous system (CNS) disease
multi-dimensional multi-omics marker MDMMTM (Multi-dimensional
Marker) algorithm platform builds brain disease digital targets and
digital pathology based on a high-value, multi-dimensional omics
database of millions of precise cohort studies of brain diseases
(Digital PathologyTM) model, and personalized brain disease digital
twins based on individual characteristics to achieve clinical
precision diagnosis and treatment of central nervous system
diseases (Precision CNS). Multidimensional and multi-omics markers
include: Functional Biomarker IIPETM, Biological
Marker IECETM, Cognitive & Behavior Biomarker PSNETM.
Core products include: GenAI large language model brain disease
screening platform, AI precision diagnostic equipment, personalized
neuromodulation treatment equipment, GenAI large language model
digital human personalized psychological consultant and AI drug
clinical research platform. Currently, in response to the huge
unmet clinical needs, the pipeline under development covers
depression, anxiety, Alzheimer's disease, bipolar disorder, autism,
attention deficit and hyperactivity disorder, sleep disorders,
pain, etc. and are at different clinical stages. Also, established
partnerships have been made with world-renowned pharmaceutical
companies and insurance companies.
About The9 Limited
The9 Limited (The9) is an Internet company listed on Nasdaq in
2004. The9 aims to become a global diversified high-tech Internet
company, and is engaged in blockchain business including the
operation of cryptocurrency mining. The9 is also
stepping into AI application business in different industries.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/a-new-generation-of-antidepressant-drug-precision-treatment-based-on-revolutionary-ai-technology-is-born-302116549.html
SOURCE The9 Limited
